The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR TKI-responsive, advanced non-small cell lung cancer (NSCLC) that subsequently progresses.
B. Halmos
Research Funding - OSI Pharmaceuticals
P. Fu
No relevant relationships to disclose
N. A. Pennell
Consultant or Advisory Role - Boehringer Ingelheim
Research Funding - Genentech
G. A. Otterson
Consultant or Advisory Role - Celgene; Genentech
Research Funding - Celgene; Genentech; Pfizer; Tragara Pharmaceuticals
T. Mekhail
Consultant or Advisory Role - Genentech
Honoraria - Genentech; Lilly
M. R. Snell
No relevant relationships to disclose
J. P. Kuebler
No relevant relationships to disclose
S. M. Gadgeel
Consultant or Advisory Role - Genentech; OSI Pharmaceuticals
Honoraria - Genentech; OSI Pharmaceuticals
A. Conrad
No relevant relationships to disclose
A. T. Stefanski
Employment or Leadership Position - OSI Pharmaceuticals
Stock Ownership - OSI Pharmaceuticals
A. Dowlati
Research Funding - OSI Pharmaceuticals